BTIG analyst Thomas Shrader reiterated a Buy rating and $147.00 price target on Bright Minds Biosciences Inc. (NASDAQ: DRUG).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE